Plasminogen activator inhibitor-1 levels in severe and morbid obesity. Effect of weight loss and influence of 4G/5G polymorphism

Abstract Introduction An association between an increase in plasminogen activator inhibitor type 1 and obesity has been described. It has also been shown that a decrease in adiposity has beneficial effects. However, less information is available regarding morbid obesity and hypofibrinolysis. The aim...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Thrombosis research 2008-01, Vol.122 (3), p.320-327
Hauptverfasser:	Solá, Eva, Vayá, Amparo, España, Francisco, Castelló, Remedios, Ramón, Luis A, Hernández-Mijares, Antonio, Vicente, Vicente, Estellés, Amparo
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Biological and medical sciences Blood and lymphatic vessels Blood. Blood coagulation. Reticuloendothelial system Cardiology. Vascular system Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous Female Fibrinolysis Genotype Hematology, Oncology and Palliative Medicine Humans Insulin resistance syndrome Male Medical sciences Middle Aged Morbid obesity Obesity, Morbid - genetics Obesity, Morbid - metabolism PAI-1 Pharmacology. Drug treatments Plasminogen Activator Inhibitor 1 - blood Plasminogen Activator Inhibitor 1 - genetics Polymorphism, Genetic Promoter Regions, Genetic - genetics Severity of Illness Index Weight Loss - physiology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!